MX2014008283A - Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. - Google Patents

Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.

Info

Publication number
MX2014008283A
MX2014008283A MX2014008283A MX2014008283A MX2014008283A MX 2014008283 A MX2014008283 A MX 2014008283A MX 2014008283 A MX2014008283 A MX 2014008283A MX 2014008283 A MX2014008283 A MX 2014008283A MX 2014008283 A MX2014008283 A MX 2014008283A
Authority
MX
Mexico
Prior art keywords
prolonged release
frequency
methods
reduce
formulation
Prior art date
Application number
MX2014008283A
Other languages
English (en)
Spanish (es)
Inventor
David A Dill
Original Assignee
Wellesley Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/343,332 external-priority patent/US20120135050A1/en
Priority claimed from US13/424,000 external-priority patent/US8236857B2/en
Priority claimed from US13/487,348 external-priority patent/US20120244221A1/en
Application filed by Wellesley Pharmaceutical Llc filed Critical Wellesley Pharmaceutical Llc
Publication of MX2014008283A publication Critical patent/MX2014008283A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Guiding Agricultural Machines (AREA)
  • Power-Operated Mechanisms For Wings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
MX2014008283A 2012-01-04 2012-08-22 Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta. MX2014008283A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13/343,332 US20120135050A1 (en) 2010-07-08 2012-01-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/424,000 US8236857B2 (en) 2010-07-08 2012-03-19 Extended-release formulation for reducing the frequency of urination and method of use thereof
US13/487,348 US20120244221A1 (en) 2010-07-08 2012-06-04 Extended-release formulation for reducing the frequency of urination and method of use thereof
PCT/US2012/051888 WO2013103390A1 (en) 2012-01-04 2012-08-22 Extended-release formulation for reducing the frequency of urination and method of use thereof

Publications (1)

Publication Number Publication Date
MX2014008283A true MX2014008283A (es) 2015-03-03

Family

ID=48745355

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008283A MX2014008283A (es) 2012-01-04 2012-08-22 Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.

Country Status (13)

Country Link
US (3) US8685453B2 (Direct)
JP (4) JP2015503583A (Direct)
KR (2) KR20180025993A (Direct)
AU (2) AU2012363789B2 (Direct)
BR (1) BR112014016661A8 (Direct)
CA (1) CA2856677A1 (Direct)
IL (1) IL232715A0 (Direct)
MX (1) MX2014008283A (Direct)
MY (1) MY173582A (Direct)
RU (1) RU2603471C2 (Direct)
SG (1) SG11201500407XA (Direct)
WO (1) WO2013103390A1 (Direct)
ZA (1) ZA201404606B (Direct)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
CN106908604B (zh) 2011-07-18 2019-01-29 重症监护诊断股份有限公司 治疗心血管疾病和预测运动疗法功效的方法
WO2013149022A1 (en) * 2012-03-30 2013-10-03 Givaudan S.A. N-acyl proline derivatives as food flavouring compounds
SG11201610383YA (en) * 2014-06-06 2017-02-27 Wellesley Pharmaceuticals Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
BR112017006141A2 (pt) * 2014-09-24 2018-02-06 Wellesley Pharmaceuticals Llc composições farmacêuticas e seus usos e métodos para reduzir espasmos na bexiga de paciente
JP2018526442A (ja) * 2015-09-01 2018-09-13 ウェルズリー ファーマスーティカルズ、エルエルシー 遅延放出製剤、その作製および使用方法
HK1256098A1 (zh) * 2015-09-01 2019-09-13 韦尔斯利医药有限公司 延缓、延迟和立即释放型制剂及其制造方法和用途
WO2017058436A1 (en) * 2015-09-30 2017-04-06 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
TW201726114A (zh) * 2015-11-23 2017-08-01 魏斯理製藥公司 降低排尿頻率之組成物、其製備方法、及其應用
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
JP2019069991A (ja) * 2018-12-27 2019-05-09 ウェルズリー ファーマスーティカルズ、エルエルシー 膀胱痙攣を低減するための医薬製剤およびその使用の方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG80535A1 (en) * 1991-09-06 2001-05-22 Mcneilab Inc Composition comprising a tramadol material and acetaminophen and its use
EP1005861B1 (en) * 1997-04-11 2005-06-29 Nippon Shinyaku Co., Ltd. Remedies for frequent urination and urinary incontinence
US7138393B2 (en) * 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
JP3660979B2 (ja) * 2000-09-05 2005-06-15 国立大学法人金沢大学 夜間頻尿症の治療剤、夜間頻尿症の予防剤
RU2193401C1 (ru) * 2001-04-02 2002-11-27 Аль-Шукри Салман Хасунович Способ лечения гиперактивности мочевого пузыря
JPWO2003043655A1 (ja) * 2001-11-19 2005-03-10 小野薬品工業株式会社 頻尿の治療剤
BR0307772A (pt) * 2002-02-19 2004-12-07 Pharmacia Corp Uso de inibidores da ciclooxigenase e de agentes antimuscarìnicos para o tratamento da incontinência
WO2004007495A1 (ja) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited ピロロピリジン誘導体およびその用途
KR100522239B1 (ko) * 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
US20050152905A1 (en) * 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20040054008A1 (en) * 2002-09-13 2004-03-18 Tohru Araki Medicament for treatment of nocturia
WO2004026308A1 (en) * 2002-09-21 2004-04-01 Shuyi Zhang Sustained release compound of acetamidophenol and tramadol
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
AU2004224322A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
DE10356112A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
US20060045912A1 (en) * 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
WO2006102029A2 (en) * 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence
EP1871372A4 (en) * 2005-04-08 2010-06-02 Neuromed Pharmaceuticals Ltd COMBINATION THERAPY WHICH INCLUDES AN AGENT BLOCKING CALCIUM CHANNELS OF TYPE N FOR THE RELIEF OF PAIN
BRPI0613547A2 (pt) * 2005-07-20 2011-01-18 Panacea Biotec Ltd forma de dosagem de liberação modificada e respectivo uso
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US20080085314A1 (en) * 2005-07-29 2008-04-10 Shalaby Shalaby W Solid oral formulations for combination therapy
WO2007072503A2 (en) * 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
US20070237816A1 (en) * 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief
AU2007276874B2 (en) 2006-07-28 2010-08-19 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
US20080057122A1 (en) * 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
MX2010001789A (es) * 2007-08-15 2010-03-10 Mcneil Ppc Inc Regimen de dosificacion de ibuprofeno de liberacion inmediata y liberacion sostenida.
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
JP2018016869A (ja) * 2016-07-29 2018-02-01 日立化成株式会社 アルミニウム系多孔質体及びその製造方法

Also Published As

Publication number Publication date
WO2013103390A1 (en) 2013-07-11
RU2603471C2 (ru) 2016-11-27
RU2014131285A (ru) 2016-02-20
JP2017031172A (ja) 2017-02-09
SG11201500407XA (en) 2015-03-30
US20130216620A1 (en) 2013-08-22
IL232715A0 (en) 2014-07-31
NZ626619A (en) 2017-03-31
NZ732149A (en) 2018-11-30
AU2017203418B2 (en) 2019-01-17
CA2856677A1 (en) 2013-07-11
NZ721818A (en) 2017-07-28
US20150272968A1 (en) 2015-10-01
JP2018087217A (ja) 2018-06-07
KR20140108675A (ko) 2014-09-12
US8685453B2 (en) 2014-04-01
KR20180025993A (ko) 2018-03-09
AU2017203418A1 (en) 2017-06-08
ZA201404606B (en) 2015-11-25
AU2012363789B2 (en) 2017-04-13
BR112014016661A2 (pt) 2017-06-13
US20140154320A1 (en) 2014-06-05
AU2012363789A1 (en) 2014-07-17
AU2012363789A2 (en) 2014-07-24
MY173582A (en) 2020-02-04
BR112014016661A8 (pt) 2017-07-04
JP2020037575A (ja) 2020-03-12
JP2015503583A (ja) 2015-02-02

Similar Documents

Publication Publication Date Title
MX2014008284A (es) Formulacion de liberacion retardada para reducir la frecuencia de orinar y metodos de uso de esta.
MX2014008283A (es) Formulacion de liberacion prolongada para reducir la frecuencia de orinar y metodos de uso de esta.
BR112014019262A8 (pt) Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
MY174090A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
MX392839B (es) Liberacion autorregulada de ingrediente farmaceutico activo.
CO6720961A2 (es) Imidazopiridazinas sustituidas
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
DOP2010000331A (es) Formulacion de medicamento solida con liberacion retardada
MX2015011316A (es) Imidazopiridazinas sustituidas.
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2016000007A (es) Pirazolpiridinas sustituidas
WO2012145575A3 (en) Therapy for leukemia
CO6660486A2 (es) Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
MX357704B (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
AR087488A1 (es) Uso de composiciones para retrasar el inicio de la fase catagena del cabello
BR112014018426A8 (pt) Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
CL2015001368A1 (es) Metodo para anticoncepcion controlada que comprende administrar una preparacion farmaceutica que comprende levonorgestrel y un inhibidor de la cox; uso de la composicion farmaceutica en la anticoncepcion "a la carta".
IN2014DN10134A (Direct)